Clinical Trial Update: MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas [Phase 2]

View source ↗

Summary

Phase 2 trial update for the MEK inhibitor selumetinib in adults with Neurofibromatosis Type 1 and inoperable plexiform neurofibromas; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibromas

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) | Phase 2 | Status: ACTIVE_NOT_RECRUITING